- Market Capitalization, $K 530,797
- Shares Outstanding, K 88,319
- Annual Sales, $ 143,010 K
- Annual Income, $ -400,420 K
- 60-Month Beta 1.78
- Price/Sales 2.76
- Price/Cash Flow N/A
- Price/Book N/A
|Period||Period Low||Period High||Performance|
| || |
-0.57 (-8.46%)since 01/22/21
| || |
+1.72 (+39.29%)since 11/24/20
| || |
-3.81 (-38.36%)since 02/24/20
Clovis (CLVS) reports wider-than-expected loss for fourth-quarter 2020. Sales of the company's sole marketed drug, Rubraca, increase year over year.
PALM BEACH, Fla., /PRNewswire/ -- In the breast cancer therapy market, the rise in the prevalence of cancer, has propelled the T-cell therapy market over the last few years and it is projected to continue...
BOULDER, Colo. (AP) _ Clovis Oncology Inc. (CLVS) on Tuesday reported a loss of $99 million in its fourth quarter.
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter and year ended December 31, 2020, and provided an update on the Company's clinical development programs and regulatory and...
NEW YORK, NY / ACCESSWIRE / February 23, 2021 / Clovis Oncology, Inc. (NASDAQ:CLVS) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 23, 2021...
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and year-end 2020 financial results on Tuesday, February 23, 2021, before the open of the U.S. financial markets. Clovis' senior management...
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced Rubraca data being presented at the American Society for Clinical Oncology (ASCO) Genitourinary Cancers Virtual Symposium 2021. These include data from...
SmarTrend identified an Uptrend for Clovis Oncology (NASDAQ:CLVS) on January 11th, 2021 at $5.42. In approximately 1 month, Clovis Oncology has returned 81.73% as of today's recent price of $9.85.
Foundation Medicine, Inc. and its collaborators today announced results from a prostate cancer study evaluating the landscape of genomic alterations identified by liquid biopsy in over 3,000 patients,...
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that two abstracts featuring data from clinical studies evaluating Rubraca(R) (rucaparib) in metastatic castration-resistant prostate cancer (mCRPC)...
|Clovis Oncology Inc|
|S&P Biotech SPDR|
|Defiance Nasdaq Junior Biotechnology ETF|
|Resources Prospect Ltd|
|Principal Healthcare Innovators Index|
|Nasdaq Biotechnology Ishares ETF|